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Objective: To compare the efﬁcacy of a 12-week non-surgical treatment program with usual care in
patients with knee osteoarthritis (OA) not eligible for total knee replacement (TKR).
Method: This two-arm parallel group assessor-blinded randomized controlled trial (RCT) included 100
adults from secondary care with knee OA, conﬁrmed by radiography (KellgreneLawrence grade 1), but
not eligible for a TKR. The 12-week non-surgical treatment program consisted of individualized pro-
gressed neuromuscular exercise, patient education, insoles, dietary advice and prescription of pain
medication if indicated, while usual care comprised two leaﬂets with information and advice on knee OA
and recommended treatments. The primary outcome was the change from baseline to 12 months in the
Knee injury and Osteoarthritis Outcome Score (KOOS)4 deﬁned as the average score for the KOOS sub-
scales of pain, symptoms, activities of daily living (ADL), and quality of life (QOL).
Results: 91% of the patients completed the 12 months follow-up on the primary outcome. Compared
with usual care, patients undergoing the treatment program improved more in KOOS4 (adjusted mean
difference (95% CI) of 9.6 (4.4e14.8)) with no serious treatment-related adverse events (AE). The number
needed to treat (NNT), deﬁned as the number of patients needed to treat for one person to improve 15%
was 7.2. Secondary outcomes supported the primary ﬁndings.
Conclusion: In patients with mostly moderate to severe knee OA not eligible for TKR, a 12-week indi-
vidualized, non-surgical treatment program is more efﬁcacious at 12 months compared with usual care
and has few treatment-related AE.
Trial registration: ClinicalTrials.gov (NCT01535001).
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Guidelines from the European League Against Rheumatism
(EULAR)1 and the Osteoarthritis Research Society International
(OARSI)2 recommends a multimodal, individualized non-surgicalS.T. Skou, Aalborg University
ark. Tel: 45-23-70-86-40.
ussen@rn.dk (S. Rasmussen),
.dk (M.S. Rathleff), LAN@hst.
nsen), eroos@health.sdu.dk
ternational. Published by Elsevier Ltreatment program as ﬁrst line treatment for knee osteoarthritis
(OA). The core treatment is exercise, weight management (if indi-
cated) and education, while biomechanical interventions (such as
insoles) and pharmacological treatment are recommended if
indicated1,2.
While the effects from exercise or diet alone were less
convincing, the Arthritis, Diet, and Activity PromotionTrial (ADAPT)
showed that the combination of exercise and weight loss improves
pain, function3 and health-related quality of life (QOL)4 more than
healthy lifestyle advice after 18 months, indicating an additive ef-
fect when combining treatments. This was conﬁrmed by atd. All rights reserved.
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and diet is more effective than either exercise or diet alone in
improving pain and function5. However, both trials were performed
in obese community dwelling adults, and no similar high quality
trials have been conducted in OA patients with more severe disease
who are seen in secondary health care. Such information would
provide clinically relevant support for non-surgical treatment as a
viable treatment option for those with more advanced disease.
The purpose of this randomized controlled trial (RCT) was to
investigate whether a 12-week treatment program of neuromus-
cular exercise, education, diet, insoles and pain medication (the
MEDIC treatment)6 results in greater improvement in pain, func-
tion and QOL compared with usual care (information and advice on
knee OA and recommended treatments) in patients with knee OA
seen in secondary health care by an orthopedic surgeon but found
to be not eligible for a total knee replacement (TKR).
We hypothesized that the treatment program would result in
greater pain reduction, functional improvement and increase in
QOL than usual care at the 12-month follow-up.Method
Trial design
This was a parallel group assessor-blinded RCT (1:1 treatment
allocation) with follow-ups at 3, 6, and 12 months conforming to
the CONSORT statement for reporting RCTs7,8. The study was
designed to follow the principles of the Declaration of Helsinki,
approved by the local Ethics Committee of The North Denmark
Region (N-20110085), and registered at ClinicalTrials.gov
(NCT01535001).
Details of the recruitment process, full eligibility criteria, the
process of randomization and allocation concealment have been
published previously in the study protocol6.Patients and recruitment process
In the North Denmark Region, patients potentially eligible for a
TKR are referred to one of two specialized, public outpatient clinics
by their general practitioner. Patients for our study were recruited
from this population by an orthopedic surgeon from either of the
two clinics (50 patients from each clinic) between April 3, 2012 and
July 12, 2013. We enrolled 100 patients with symptomatic and
radiographically-conﬁrmed knee OA, found not eligible for TKR by
an orthopedic surgeon (decision among others factors based on
pain, function and radiographic severity9), but experiencing more
than mild limitations. Major exclusion criteria were less than mild
limitations (a score above 75 on a 0e100 worst to best scale in the
self-report questionnaire Knee injury and Osteoarthritis Outcome
Score (KOOS)4 deﬁned as the average score for the subscale scores
for pain, symptoms, activities of daily living (ADL) and QOL); pre-
vious ipsilateral knee replacement; and a mean knee pain intensity
in the previous week greater than 60 mm on a 100 mm visual
analog scale (VAS).Randomization and allocation concealment
A priori, the randomization schedule was generated in
permuted blocks of eight, stratiﬁed by clinic. The allocation
numbers were concealed in opaque envelopes prepared by a staff
member independent of the study. The envelopes were accessible
to one research assistant at each clinic, only opening them after
informed consent and baseline measures had been obtained.Study treatments
The MEDIC treatment
The 12-week MEDIC treatment consisted of ﬁve components:
education, exercise and insoles were prescribed to everyone in the
MEDIC group, with weight loss and/or pain medication prescribed
if indicated. The MEDIC treatment was delivered by physiothera-
pists and dieticians trained in delivering the treatment to ensure
proper standardization of the treatment.
Education. The education consisted of two 60-min sessions
focusing on disease characteristics, treatment and assistance to
support self-help by actively engaging the patients in the sessions
and in the treatment. The education included in this study, in
combination with neuromuscular exercise, has previously
demonstrated to be feasible and efﬁcacious in improving pain,
function and QOL10.
Neuromuscular exercise. The NEuroMuscular EXercise training
program (NEMEX), previously found feasible in patients with
moderate to severe knee OA11, was undertaken by patients twice a
week for 12 weeks with each session lasting 60 min. The exercise
program is based on neuromuscular and biomechanical princi-
ples11. It aims at restoring neutral functional alignment of the lower
extremities by obtaining compensatory functional stability and
improving sensorimotor control. It consists of warm-up and cool-
down periods with a circuit program with four exercise circles in
between. Key elements are core stability/postural function;
postural orientation, muscle strength and functional exercises. Each
participant was monitored individually with regard to pain in-
tensity during the exercise session. Progression was allowed if the
quality of the exercise could be maintained11. Details of the pro-
gram are provided elsewhere11. Following the 12 weeks of super-
vised exercise, there was a transition period of 8 weeks, where the
program was increasingly performed at home to improve long-
term adherence.
Diet. Patients with a Body Mass Index (BMI) 25 at baseline un-
derwent a 12-week dietary weight loss program consisting of four
60-min sessions aimed at reducing the body weight by at least 5%
and sustaining this weight loss to reduce symptoms12. The dietary
intervention was based on principles from motivational inter-
viewing with instructions and guidance relevant to the individual
participant13.
Insoles. Patients in the MEDIC group received an individually ﬁtted
full-length Formthotics System insole with medial arch support
(Foot Science International, Christchurch, New Zealand). Addi-
tionally, patients with a knee-lateral-to-foot position (the knee
moves over or lateral to the ﬁfth toe in three or more of ﬁve trials)
using the valid and reliable single limb mini squat test14, had a 4
lateral wedge added to their insole.
Medicine. The patients were offered pain medication if the ortho-
pedic surgeon considered it necessary for participation in the ex-
ercise. If no contraindications were evident, they were prescribed
1 g paracetamol four times, 400 mg ibuprofen three times, and
20 mg pantoprazol daily. The prescription was reassessed every 3
weeks. The patients were instructed to contact the physiotherapist
if they questioned the continuation of the medicine.
Booster sessions. After the 12-week MEDIC treatment and the 8-
week transition period but prior to the 12-month follow-up, the
physiotherapist contacted the patients monthly by telephone to
support the continuation of exercise and physical activity.
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two additional 30-min telephone consultations with the dietician
between the 3-month follow-up and the 12-month follow-up.
Usual care
Patients allocated to usual care were given two standardized
information leaﬂets (also given to the MEDIC group). The ﬁrst
leaﬂet (four pages) holds information on knee OA with regard to
etiology, symptoms, functional limitations, recommended treat-
ments and general advice on how to address symptoms. The second
leaﬂet (two pages) contains information onwhere in region you can
seek advice regarding treatment and general information on how
to sustain a healthy lifestyle (focusing on diet, smoking, alcohol and
physical activity). Content provided to the usual care group was
prepared to reﬂect current treatment of patients with knee OA in
clinical practice, found to be suboptimal compared to clinical
guidelines in several countries15,16.
Outcomes
All follow-ups were carried out at the Department of Occupa-
tional Therapy and Physiotherapy, Aalborg University Hospital by
the same outcome assessor speciﬁcally trained in all aspects of the
assessments, unafﬁliated with the treatment sites, and blinded to
treatment allocation.
Primary outcome measure
The pre-speciﬁed primary outcome was the change from base-
line to 12 months in KOOS4 (including follow-ups at 3 and 6
months), with scores ranging from 0 (worst) to 100 (best). KOOS4
was deﬁned as the average score for the subscale scores for pain,
symptoms, ADL and QOL, each containing multiple items scored
from 0 to 4 on a Likert scale17,18. KOOS is a valid, reliable and
responsive patient-reported outcome measure previously applied
in studies with short-term and long-term follow-up of knee OA19.
Secondary outcome measures
Pre-speciﬁed secondary outcomes were the change from base-
line to the 12 months follow-up (including follow-ups at 3 and 6
months) in a range of outcomes, as described below.
KOOS subscales. Changes in the ﬁve KOOS subscales scores (the ﬁfth
scale being difﬁculty in sports and recreational activities) were
used to support the primary outcome and enable clinical inter-
pretation of the contributions of the individual subscales to the
overall KOOS4 score20.
Functional performance. Change in functional performance was
assessed using time from the Timed Up and Go test21 and mean
time from two 20-m walk tests22.
Self-reported general health. The descriptive index (EQ-5D Index)
and the EQ VAS from the EQ-5D 5 Dimensional form 3 level version
(EQ-5D-3L) was applied to investigate changes in general health23,24.
Weight. Weight change was measured in kg without shoes at the
same time of the day and on the same scales (seca 813, Seca Gmbh
& Co. Kg., Hamburg, Germany).
Usage of pain medication. This was deﬁned as any pain medication
taken on a regular basis during the previous week (type, dosage,
quantity per week) at baseline and the 12-month follow-up. The
results were dichotomized (pain medication yes/no) due to non-
uniformity of the distribution of pain medication intake among
the patients.Adverse events (AE). The number of AE and serious adverse events
(SAE) during the 12 months were recorded in both groups. AEs and
SAEs were identiﬁed in three ways (by the physiotherapist, in
hospital records and at follow-ups) and categorized as involving the
index knee or sites other than index knee.
Statistical analysis
A detailed description of the statistical analysis was made
publically available before any analyses commenced25. All analyses
were conducted by an independent statistician blinded to group
allocation. To reduce the risk of interpretation bias26, blinded re-
sults from the primary, secondary and exploratory analyses (Group
A compared with Group B) were presented to the authors, who
conducted two blinded interpretations. Only after agreeing on the
interpretations, was the randomization code broken (see
Supplementary Appendix 1).
Sample size
The sample size needed to detect a 10-point difference between
groups in KOOS4 and the individual KOOS subscales (standard de-
viation of 14, power of 90% and P-value of 0.05 (two-sided)) was 41
patients in each group. To account for possible TKR during follow-
up and missing data, the drop-out rate was set to 20% and a total of
100 patients were randomized.
Primary and secondary analyses
Both the primary and secondary outcomes were analyzed in
intention-to-treat (ITT) and per-protocol (PP) analyses. The PP an-
alyses were considered secondary to the ITT analyses and con-
ducted to investigate the potential beneﬁts of the MEDIC
treatment7,8. The ITT population retained those randomized to the
two treatment arms (n ¼ 100). For the MEDIC group, the PP pop-
ulation was deﬁned as those having had 18 out of the 24 exercise
sessions and not having had a TKR, while it was identical to the ITT
population except for those having had a TKR for the usual care
group.
Between-group comparisons of treatment effect for the primary
and secondary outcomes (except for usage of pain medication and
the occurrence of AE) were made using a mixed effects model with
participant being a random factor and follow-up (baseline, 3, 6 and
12 months), treatment arm (MEDIC, usual care), site (Frederik-
shavn, Farsoe) and baseline values being ﬁxed factors. Baseline
values were added as a covariate. Furthermore, interaction between
follow-up and treatment arm were included in the model. Mean
between-group differences and two-sided 95% CI are presented to
assess superiority.
The relative risks associated with usage of pain medication and
occurrence of AE were estimated and compared between groups
using a Poisson regression model with a robust error variance for
the conﬁdence intervals27.
Number needed to treat (NNT)
NNT estimates the number of people who would need to go
through the MEDIC treatment for one person to have a 15%
improvement28,29 in KOOS4 and the KOOS subscale scores, from
baseline to the 12-month follow-up compared with the usual care
group. NNT was estimated using the formula 1/(MERUER), with
MER being the event rate (proportion of responders, i.e., patients
improving at least 15%) in the MEDIC group and UER, the event rate
in the usual care group, with 95% CIs derived from the reciprocal
transformation of the CIs for the difference in proportions30.
The signiﬁcance level was set at P < 0.05 and all analyses were
carried out in Stata 13 (StataCorp, College Station, TX, USA).
Fig. 1. Flow of patients in the study. KeL score ¼ KellgreneLawrence score; KOOS4 ¼ The average score for the subscale scores for pain, symptoms, ADL and QOL from the KOOS,
VAS.
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Participant characteristics
The ﬂow of patients through the trial is illustrated in Fig. 1.
In total, 100 were randomized with 47/50 (94%) in the MEDICgroup and 44/50 (88%) in the usual care group completing
the 12 months follow-up. All 100 were included in the ITT
analysis, while 23/47 (49%) in the MEDIC group and 39/44 (89%)
in the usual care group were included in the PP analysis.
Characteristics of treatment groups at baseline are presented in
Table I.
Table I
Baseline characteristics
Baseline characteristics MEDIC Usual care
Women, n (%) 26 (52) 25 (50)
Age (years), mean (SD) 64.8 (8.7) 67.1 (9.1)
Weight (kg), mean (SD) 88.1 (17.6) 85.0 (16.3)
BMI, mean (SD) 30.6 (5.6) 29.4 (5.2)
Study knee, n right (%) 18 (36) 27 (54)
Bilateral knee pain, n (%) 18 (36) 21 (42)
Duration of knee symptoms, n (%)
0e6 months 4 (8) 2 (4)
6e12 months 9 (18) 6 (12)
1e2 years 10 (20) 5 (10)
2e5 years 11 (22) 13 (26)
5e10 years 4 (8) 8 (16)
More than 10 years 12 (24) 16 (32)
Radiographic knee OA severity (KellgreneLawrence), n (%)
Grade 1 7 (14) 11 (22)
Grade 2 13 (26) 15 (30)
Grade 3 13 (26) 10 (20)
Grade 4 17 (34) 14 (28)
Charlson comorbidity index, n (%)
0 19 (38) 21 (42)
1 26 (52) 19 (38)
2 5 (10) 8 (16)
3 or above 0 (0) 2 (4)
Living alone, n (%) 8 (16) 17 (34)
College education or equivalent, n (%) 22 (44) 25 (50)
Employment status, n (%)
Working full-time or part-time 13 (26) 12 (24)
Unemployed 2 (4) 1 (2)
Sick leave 4 (8) 3 (6)
Pensioner 31 (62) 34 (68)
Prior treatment of knee OA, n (%)
Exercise 3 (6) 2 (4)
Passive treatments* 10 (20) 9 (18)
Paracetamol 17 (34) 17 (34)
NSAIDs 19 (38) 19 (38)
Opioids and opioid-like drugs 6 (12) 2 (4)
Cortisone injection 3 (6) 3 (6)
Surgery
Meniscectomy 2 (4) 5 (10)
Debridement 6 (12) 9 (18)
Other knee surgery 3 (6) 2 (4)
KOOS scores
KOOS4 48.9 (11.8) 53.2 (12.1)
Pain 51.6 (14.3) 53.6 (13.7)
Symptoms 54.6 (15.9) 59.5 (18.3)
ADL 55.5 (17.1) 60.4 (16.4)
Sport/Rec 24.5 (18.2) 23.0 (16.5)
QOL 34.0 (12.4) 39.5 (14.5)
Functional performance, mean (SD)
Time (s) from the Timed Up and Go test 7.8 (2.3) 8.1 (2.5)
Time (s) from the 20-m walk test 10.9 (2.3) 11.0 (2.4)
EQ-5D, mean (SD)
EQ-5D index 0.660 (0.160) 0.689 (0.145)
EQ VAS 64.9 (18.6) 68.2 (21.3)
Have used pain medication in the last week, n (%) 32 (64) 30 (60)
* This included massage, acupuncture, stretching, therapeutic ultrasound, laser therapy, and manipulation.
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ITT analysis
Therewas a statistically signiﬁcant difference in change (95% CI)
of 11.3 (5.8e16.8; crude) or 9.6 (4.4e14.8; adjusted) units between
groups in the primary outcome (KOOS4) covering pain, symptoms,
ADL, and QOL, favoring the MEDIC group. The MEDIC group had a
median improvement of 37.6% while the usual care group improved
by 10.3% in the KOOS4 score (Table II).
PP analysis
The PP analysis conﬁrmed the ﬁnding from the ITT analysis with
a statistically signiﬁcant difference in change (95% CI) of 10.4(3.7e17.1; crude) or 8.8 (2.5e15.1; adjusted) units between groups
in KOOS4.
Changing the compliance to 12 instead of 18 out of the 24 ex-
ercise sessions did not change the results (data not shown).
Secondary outcomes
ITT analysis
Change in the KOOS subscales of Pain, Symptoms, ADL and QOL,
time for the 20-m walk test and the EQ-5D index supported the
ﬁndings from the primary analysis showing statistically signiﬁcant
differences between groups in favor of the MEDIC group (Table II
and Fig. 2).
Table II
Outcome at 12 months
Outcome (number of data pointsMEDIC,
number of data pointsusual care)*
Improvement in MEDIC
group (95% CI)
Improvement in usual
care group (95% CI)
Between-group difference
(crude) (95% CI)
Between-group difference
(adjusted)y (95% CI)
Mean (months) follow-up after baseline 12.4 (12.2 to 12.7) 12.4 (12.2 to 12.6)
Primary endpoint: mean change in KOOS4
from baseline to 1 yr (184, 187)
18.2 (13.0 to 23.4) 7.1 (1.4 to 12.9) 11.3 (16.8 to 5.8) 9.6 (14.8 to 4.4)
Secondary endpoints
Mean change in KOOS subscales score
Pain (185, 187) 18.7 (12.9 to 24.6) 9.3 (2.9 to 15.6) - 9.7 (16.1 to 3.3) 9.0 (15.0 to 3.0)
Symptoms (185, 187) 16.3 (10.6 to 22.0) 7.7 (1.5 to 13.9) 8.6 (14.9 to 2.2) 6.9 (12.8 to 0.9)
ADL (185, 187) 18.7 (12.6 to 24.8) 5.9 (0.8 to 12.6) 13.2 (19.9 to 6.6) 11.2 (17.1 to 5.4)
Sport/Rec (183, 185) 16.0 (7.8 to 24.1) 12.0 (4.8 to 19.3) 4.0 (11.9 to 3.8) 4.7 (12.2 to 2.8)
QOL (184, 187) 19.0 (12.9 to 25.2) 5.5 (1.1 to 12.1) 13.5 (19.8 to 7.1) 10.9 (16.8 to 5.0)
Mean change in time (s) from the Timed
Up and Go test (169, 158)
1.4 (1.9 to 0.9) 1.1 (1.7 to 0.5) 0.3 (0.3 to 1.0) 0.4 (0.1 to 1.0)
Mean change in time (s) from the 20-m
walk test (170, 160)
1.2 (1.6 to 0.8) 0.6 (1.1 to 0.1) 0.6 (0.0 to 1.2) 0.7 (0.1 to 1.3)
Mean change in EQ-5D
EQ-5D index (184, 187) 0.140 (0.095 to 0.186) 0.075 (0.018 to 0.132) 0.072 (0.127 to 0.016) 0.060 (0.106 to 0.015)
EQ VAS (183, 187) 5.3 (0.4 to 11.0) 7.2 (0.1 to 14.2) 1.0 (6.9 to 8.8) 2.2 (4.9 to 9.3)
Mean weight change (kg)z (147, 125) 2.4 (3.8 to 1.1) 2.4 (4.1 to 0.6) 0.1 (1.4 to 1.3) 0.1 (1.4 to 1.3)
* n refers to the number of data points out of 200 in each group (50 at baseline, 3, 6 and 12 months).
y The results were adjusted for follow-up (baseline, 3, 6, and 12months), site (Frederikshavn, Farsoe), baseline values and interaction between follow-up and treatment arm.
z Only for the 42 and 37 patients with a BMI25 at baseline in the MEDIC group and the usual care group, respectively.
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Up and Go test, EQ-5D VAS, body weight and usage of pain medi-
cationwere not signiﬁcantly different between the groups (Tables II
and III and Fig. 2).
Non-SAE (most commonly knee pain of short duration) were
more common in the MEDIC group, while SAE (most commonly
TKR) were more common in the usual care group. There were,
however, no signiﬁcant differences between groups in the number
of AE (Table IV).
Within-group analysis. Both groups improved signiﬁcantly in all
primary and secondary outcomes with the exception of EQ VAS
where theMEDIC group did not improve, and KOOS ADL, KOOS QOL
and usage of pain medication where the usual care group did not
improve (Tables II and III).
PP analysis
The PP analysis showed statistically signiﬁcant differences in
change (95% CI; adjusted) of 8.2 (0.8e15.7), 11.1 (3.6e18.5) and 8.6
(1.4e15.8) units between groups in the KOOS subscale scores of
Pain, ADL, and QOL, favoring the MEDIC group.
NNT
The NNT ranged from 3.7 (KOOS QOL) to 7.2 (KOOS Pain and
KOOS4) (Table V).
Treatment-related variables
Table VI presents compliance with education, exercise, diet and
usage of insoles. See Supplementary Appendix 2 for details of other
treatments and consultations during follow-up.
Discussion
This RCT showed that a 12-week individualized, non-surgical
treatment program was associated with greater improvements in
pain, function and QOL after 12 months compared with standard
information and advice, in patients with mostly moderate to severe
radiographically-conﬁrmed knee OA and more than mild limita-
tions, but not eligible for TKR. Furthermore, the treatment programhad no serious treatment-related AE. The results highlight that
clinically relevant long-term effects from combined non-surgical
treatments are achievable also in patients with more severe knee
OA seen in secondary health care.
Comparison with other studies
Our study extends the ﬁndings from previous studies performed
in community-dwelling adults and in primary care to those with
more severe OA seen in secondary health care. Two previous RCTs
have investigated the long-term efﬁcacy of a combination of two or
more of the recommended treatments as compared with usual care
for knee OA3,28. The ADAPT3 trial, investigating the efﬁcacy of
combining exercise and weight loss, was undertaken in obese
(mean BMI z 34) community dwellers with less severe knee OA
(mean pain ofz35 out of 100 andmedian KellgreneLawrence of 2),
while the ESCAPE-knee pain trial, investigating the efﬁcacy of
combining exercise and education, included borderline obese
(BMIz 30) patients with less severe symptomatic knee OA (mean
painz38 out of 100) without radiographically-conﬁrmed knee OA
from primary care. We included a borderline obese (mean
BMIz 30) study population with more severe knee OA (mean pain
53 out of 100 and median KellgreneLawrence grade 3) seen in
secondary health care. Despite more severe disease, the pain-
relieving effect from combined non-surgical treatments was
replicated. This highlights the novelty and clinical signiﬁcance of
our study.
The ADAPT3 trial demonstrated that the combination of super-
vised exercise and diet for 4 months and individualized booster
sessions during the remaining 14 months of the trial was more
efﬁcacious than usual care for improving pain, function3 and QOL4
in patients with knee OA at 18 months. Despite a shorter inter-
vention (3 months) and only monthly telephone booster sessions,
we found larger improvements in pain (36%) and function (37%) in
the treatment group of our study comparedwith the improvements
found in pain (30%) and function (24%) in the treatment group of
ADAPT3. The ESCAPE knee pain trial found that even though pain
and function improved more in the group receiving exercise and
education immediately after the intervention, these improvements
were not sustained at 6, 18 and 30 months28. After adjusting for
follow-up time, treatment group and baseline function, the mean
Fig. 2. Mean subscale scores at all time points for the KOOS subscales of pain (A), symptoms (B), ADL (C), sports and recreational activities (Sport/Rec; D), and QOL (E) for the groups
randomized to either a 12-week non-surgical treatment program consisting of neuromuscular exercise, education, diet, insoles, and pain medication (the MEDIC group) or usual
care (the usual care group). The error bars indicate 95% conﬁdence intervals.
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term follow-ups, being approximately ﬁve on a 0e100 scale after
18 months32. Our study found that the effects on pain and function
after the interventionwere achieved at 3months and sustained at 6
and 12 months, and that the difference in function between
treatment groups was twice as large as in the ESCAPE knee pain
trial. The improved efﬁcacy demonstrated in our study could be
attributed to differences in study populations. However, it seems
more likely that the improved efﬁcacy is due to differences in the
interventions given in the studies. First of all, in addition to exer-
cise, our treatment program comprised both education and a di-
etary weight loss program, and moreover, insoles and analgesics ifneeded. Including both a dietary weight loss program and educa-
tion could be essential, since weight loss is known to be an
important contributor to improved pain and function12 and since
the education informs the patients about how to control and
address OA-related issues on their own, even after the supervised
intervention has stopped. Secondly, even though the ADAPT trial
included more exercise sessions than our study (3 days/week of
facility-based exercise for 4e6 months; 64% adherence to exercise
and diet comparable to adherence in our study), the type and
composition of the exercise differed between the studies. While the
exercise in ADAPT primarily consisted of aerobic walking without
focus on alignment3, our neuromuscular exercise program aimed at
Table IV
Adverse events
AE* MEDIC Usual care P value
Number of events
Serious events
Site other than index knee
Musculoskeletaly 1 5
Skinz 1 0
Gastrointestinalx 1 0
Otherk 3 7
Subtotal 6 12 0.22
Index knee
Knee arthroscopy¶ 3 1
TKR¶ 3 5
During TKR surgery# 0 1
After TKR surgery** 1 5
Subtotal 7 12 0.41
All serious events 13 24 0.13
Non-serious events
Sites other than index kneeyy 6 4 0.51
Index knee
Pain 14 12
Swelling 3 1
Subjective instability 0 0
Decreased range of motion 1 0
Joint distortion 0 0
Otherzz 1 2
Subtotal 19 15 0.58
All non-serious events 25 19 0.46
* This table includes all serious and non-SAE that occurred during the 12-month
study period, but not necessarily had a causal relationship with the treatment
administered. SAE include those having the potential to signiﬁcantly compromise
the clinical outcome, result in signiﬁcant disability or incapacity, requiring inpatient
or outpatient hospital care, and those considered to prolong hospital care, to be life-
threatening, or to result in death. Non-serious comprise all other AE.
y In the MEDIC group this included pain and swelling of the contralateral foot
leading to arthrodesis. In the usual care group it included fracture of os sacrum; gout
(n ¼ 2); low back pain radiating to the leg; and fracture of collum femoris.
z Erysipelas.
x Intestinal cancer.
k In the MEDIC group this included pneumonia; Guillain-Barre syndrome; and
death. In the usual care group, it included death; ovarian cyst; heart problems;
severe physical decline due to inﬂuenza; renal-artery stenosis; Atherosclerosis
demanding angioplasty; and canalolithiasis.
¶ Only TKRs and knee arthroscopies reported to the project physiotherapist, at
follow-ups, and from hospital records at public hospitals in the North Denmark
Region were included, since private hospitals and hospitals outside the region use
different registration systems. Since TKRs and knee arthroscopies were performed
due to worsening of symptoms, they were considered to be AE.
# Low hemoglobin counts leading to blood transfusion.
** In the MEDIC group, this included pain without loosening of the prosthesis. In
the usual care group, it included pain without loosening of the prosthesis (n ¼ 3);
instability; and swelling.
yy In the MEDIC group this included Achilles tendinopathy (n ¼ 2); a broken toe;
foot pain of short duration; intermittent hip pain; and sciatic nerve pain of short
duration. In the usual care group, it was an ankle sprain (grade I), intermittent hip
pain; pain in the contralateral knee; and a hamstring strain.
zz In the MEDIC group, this was calor around the knee. In the usual care group, it
included rubor; and calor around the knee.
Table III
Usage of pain medication at 12 months
Outcome MEDIC group (95% CI) Usual care group (95% CI)
Proportion of users of pain medication* (nMEDIC, nusual care)
Baseline (50, 50) 0.64 (0.50e0.76) 0.56 (0.42e0.69)
12 months (46, 44) 0.39 (0.26e0.54) 0.57 (0.42e0.71)
Risk ratio for taking pain medication at 12 months vs baseline
Adjusted estimatey,z 0.61 (0.43e0.88) 1.02 (0.78e1.34)
Risk ratio for taking pain medication at 12 months in the usual care group vs
MEDIC group
Adjusted estimatey,z 1.45 (0.93e2.27) e
* User of pain medication was deﬁned as a patient taking pain medication of any
kind on a regular basis during the last week.
y The estimates were adjusted for site.
z The crude estimate was similar to the adjusted estimate (data not shown).
S.T. Skou et al. / Osteoarthritis and Cartilage 23 (2015) 1465e14751472restoring neutral functional alignment by obtaining compensatory
functional stability and improving sensorimotor control. It is
possible that larger improvements could be foundwhen addressing
varusevalgus control deﬁcits, and the lack of capacity to stabilize
the joint, which is often seen in patients with knee OA33. Thirdly,
the ESCAPE knee pain trial comprised only 12 supervised sessions
lasting 35e40 min without any transition period or booster ses-
sions following the intervention28. In contrast, the MEDIC treat-
ment consisted of 24 supervised exercise sessions followed by a
transition period to gradually increased exercise at home, and
thereafter monthly telephone booster sessions to improve long-
term adherence.
This is supported by a recent meta-regression analysis demon-
strating increased efﬁcacy with larger numbers of supervised ses-
sions34 and a systematic review demonstrating beneﬁcial long-
term effects in knee OA of booster sessions after the intervention
period35. Themeta-regression analysis of 49 RCTs on the immediate
efﬁcacy of exercise in knee OA demonstrated effect sizes trans-
formed into a 0e100 mm VAS scale of 8.5 for pain and 8.3 for
function, highlighting exercise as a potent treatment option in knee
OA34. While the difference in effect between groups from the
combined treatment in our study was comparable for pain
(adjusted 8.2), it was higher for function (adjusted 11.1). Pre-
cautions should be taken when comparing the studies, since the
meta-regression analysis reported immediate effects and included
a broad range of patient populations and exercise and control in-
terventions in addition to studies of varying quality. Nevertheless, it
seems the combined treatment in our study was at least as efﬁca-
cious as exercise alone immediately following treatment, and it was
maintained over the following 9 months.
Clinical implications
Our study provides evidence for orthopedic surgeons in sec-
ondary health care supporting the referral of patients not eligible
for a TKR to a non-surgical treatment program (38% improvement
in KOOS4) instead of just giving information and advice on knee OA
and recommended treatments (10% improvement). The NNT
ranged from 3.7 (QOL) to 7.2 (Pain and KOOS4) and the MEDIC
treatment had no serious treatment-related AE. A low NNT and few
treatment harms indicate a treatment being suitable and relevant
for general use in clinical care. In comparison, other well-
established and highly utilized interventions show higher NNTs
combined with higher risk of AE36,37. Antibiotics for preventing
infection in open limb fractures has a NNT of 13 to prevent one
person from infection36 and the use of antibiotics for acute maxil-
lary sinusitis has a NNT of 15 to help one patient with faster reso-
lution of symptoms while one in eight experiences side effects37.
This substantiates the clinical signiﬁcance of the low NNT and few
AE found in our study of patients with knee OA. Since radiographicseverity is unrelated to the pain-relieving effects of non-surgical
treatment38, the orthopedic surgeon can conﬁdently refer pa-
tients with knee OA to non-surgical treatment.
Strengths and limitations of the study
The strengths of the study include the evident resemblancewith
the contemporary individualized OA treatment strategy recom-
mended worldwide. As the study was embedded in secondary
health care, our results are generalizable to patients referred to
secondary health care but considered not eligible for TKR. Our
ﬁndings thus extend previous knowledge on the beneﬁts from non-
Table V
Improvements of at least 15% and NNT*
Outcome (nMEDIC, nusual care) Proportion improving at least
15% in MEDIC group (95% CI)
Proportion improving at least
15% in usual care group (95% CI)
NNTB (95% CI)
KOOS4 from baseline to 1 yr (47, 44) 0.64 (0.49e0.76) 0.50 (0.35e0.65) 7.2 (NNTB 2.9 to ∞ to NNTH 15.8)
Mean change in KOOS subscales score
Pain (47, 44) 0.64 (0.49e0.76) 0.50 (0.35e0.65) 7.2 (NNTB 2.9 to ∞ to NNTH 15.8)
Symptoms (47,44) 0.72 (0.58e0.83) 0.52 (0.37e0.67) 5.0 (2.5 to 185.4)
ADL (47, 44) 0.66 (0.51e0.78) 0.43 (0.29e0.58) 4.4 (2.3 to 35.3)
Sport/Rec (38, 32) 0.64 (0.49e0.76) 0.66 (0.51e0.79) 48.1 (NNTB 5.7 to ∞ to NNTH 4.6)
QOL (47, 44) 0.72 (0.58e0.83) 0.45 (0.31e0.60) 3.7 (2.2 to 13.5)
* NNT was estimated using the formula 1/(MER e UER), with MER being the event rate (proportion of responders, i.e., patients improving at least 15%) in the MEDIC group
and UER the event rate in the usual care group, with 95% CIs derived from the reciprocal transformation of the CIs for the difference in proportions. When the 95% CI includes
both positive and negative values, NNTB (NNT beneﬁt) and NNTH (NNT Harms) are used30,31.
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population and in primary care to this group withmore severe knee
OA. Long-term effectiveness represents a major challenge following
non-surgical treatment35. However, our study is encouraging since
it showed sustained and even improved long-term effects at the 12-
month follow-up, 9 months after the supervised intervention
stopped.
The combination of treatments and the deﬁnition of the PP
population result in some limitations to the study. Due to the
multimodal nature of the treatment program, it is unknown
whether all components of the MEDIC treatment are required for
the effect seen, while at the same time making it impossible to
identify the efﬁcacy of an individual treatment modality.Table VI
Compliance
Variable* MEDIC
Compliance with exercise during the 12 weeks,
mean sessions out of 24 (SD)
15.8 (6.9)
Got insoles, n (%) 47 (94)
Compliance with insolesy
Never use them 1 (3)
Use them every month 1 (3)
Use them every week 6 (17)
Use them every day 17 (49)
Use them all the time 10 (29)
Patient education, n sessions (%) out of 2
0 12 (24)
1 1 (2)
2 37 (74)
Compliance with aspects learned in the educationz
Never use it 0 (0)
Use it every month 0 (0)
Use it every week 10 (29)
Use it every day 13 (37)
Use it all the time 6 (17)
Dietary advice, n sessions (%) out of 4x
0 4 (10)
1 3 (7)
2 2 (5)
3 4 (10)
4 29 (69)
Compliance with aspects learned at the dieticiank
Never use it 2 (6)
Use it every month 0 (0)
Use it every week 6 (17)
Use it every day 12 (34)
Use it all the time 4 (11)
* The numbers in this table include all those randomized to theMEDIC groupwith
available data on compliance after the 12-week intervention period.
y 35 out of 47 receiving insoles answered this question (74%).
z 29 out of 38 participating in at least one of the two sessions of patient education
answered this question (76%).
x 42 patients had a BMI of 25 or above and were offered dietary advice.
k 24 out of 38 participating in at least one of the sessions with the dietician
answered this question (63%).Conclusions
At 12 months, a 12-week treatment of neuromuscular exercise,
education, usage of insoles and, if indicated, a dietary weight loss
program and pain medication is more efﬁcacious than written and
oral advice alone, in patients with knee OA found not eligible for
TKR by an orthopedic surgeon. Few treatment-related AE were
observed. Our results show that clinically relevant long-term ef-
fects from combined non-surgical treatments are possible also in
patients with more severe knee OA referred to secondary health
care.
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